Detalhe da pesquisa
1.
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.
Nat Immunol
; 23(8): 1183-1192, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35902637
2.
Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Cancer
; 130(5): 692-701, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864521
3.
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Lancet
; 402(10397): 185-195, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37290461
4.
Prognostic Factors for Survival in Patients Undergoing Surveillance After Cytoreductive Nephrectomy.
J Urol
; 210(2): 273-279, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37167628
5.
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Future Oncol
; 19(40): 2631-2640, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882432
6.
Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges.
N Engl J Med
; 390(15): 1432-1433, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38631007
7.
Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.
Cancer
; 127(21): 3946-3956, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34286865
8.
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma.
Br J Cancer
; 124(1): 237-246, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024271
9.
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma.
J Natl Compr Canc Netw
; 19(4): 432-438, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33578374
10.
A qualitative framework of non-selection factors for cytoreductive nephrectomy.
World J Urol
; 39(9): 3359-3365, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33779820
11.
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Lancet Oncol
; 21(2): 283-293, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870811
12.
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Cancer
; 126(24): 5247-5255, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975815
13.
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Br J Cancer
; 123(6): 898-904, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32587360
14.
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Br J Cancer
; 123(11): 1590-1598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32913286
15.
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
BMC Urol
; 20(1): 84, 2020 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32616076
16.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Cancer
; 125(14): 2400-2408, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951193
17.
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Lancet Oncol
; 19(12): 1688-1698, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30416077
18.
19.
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
Oncologist
; 22(3): 286-292, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220024
20.
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Invest New Drugs
; 35(6): 742-750, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28281183